Ryan Kaiponen Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 118 Cherry Ln, Ontonagon, MI 49953 Phone: 906-390-0301 |
News Archive
The National Health and Nutrition Examination Survey (NHANES) expected to be released today by the Centers for Disease Control (CDC) is on the right track with a focus on testing people's bodies for chemical contamination, say environmental health advocates working on chemical exposure issues.
Critical challenges remain in the centuries-old battles against infectious diseases, particularly as bacteria and viruses mutate and as the threat of bioterrorism grows. Responding to this need, America's biopharmaceutical research companies this year have 395 new medicines and vaccines in the pipeline to fight infectious diseases. All 395 are in later stages of development, meaning in clinical trials or under Food and Drug Administration (FDA) review.
Vitamin D and calcium are dietary requirements, but it's unclear how much is best for us. New draft findings by the United States Preventive Services Task Force conclude that for healthy, postmenopausal women, daily supplementation with low levels of vitamin D — up to 400 international units — combined with 1,000 milligrams of calcium, does not reduce fracture risk.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO was first approved in January 2012 for people with CF ages 6 and older who have at least one copy of the G551D mutation.
› Verified 7 days ago